| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $2.6M | — | -20.3% |
| SG&A Expense | $3.1M | — | -0.1% |
| Operating Income | -$5.7M | — | +10.4% |
| Net Income | -$5.6M | — | +10.9% |
| EPS (Basic) | -$0.24 | — | +25.0% |
| EPS (Diluted) | -$0.24 | — | +25.0% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $8.1M | -38.2% | +109.1% |
| Current Assets | $8.5M | -37.6% | +100.5% |
| Total Assets | $8.9M | -36.5% | +98.8% |
| Current Liabilities | $4.7M | -17.3% | -48.4% |
| Total Liabilities | $5.1M | -16.1% | -46.4% |
| Stockholders' Equity | $3.8M |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$5.0M | — | -8.6% |
| Financing Cash Flow | -$8K | — | +93.9% |
| +174.4% |